Abstract
The aim is to evaluate the efficacy and safety of Sofosbuvir- (SOF-) based direct-acting antiviral agents (DAAs) treatment for patients with genotype (GT) 3/6 hepatitis C virus (HCV) infection. Patients infected with GT 3/6 HCV and treated with SOF-based DAAs were enrolled in this prospective, open, single-center, and real-world study. Drugs included Sofosbuvir (SOF), Velpatasvir (VEL), Daclatasvir (DCV), and Ribavirin (RBV). The treatment regimens included SOF + RBV for 24 weeks, SOF + DCV ± RBV for 12/24 weeks, and SOF/VEL ± RBV for 12 weeks. A total of 54 patients were included. Age was 42.5 ± 10.4 years. Baseline HCV RNA was 6.29 ± 0.89log10 IU/mL. The numbers of GT 3a, 3b, and 6a patients were 10, 12, and 32, respectively. The numbers of chronic hepatitis, compensated cirrhosis, and decompensated cirrhosis patients were 39, 9, and 6, respectively. In patients with chronic hepatitis C and liver cirrhosis, sustained virological response 12 weeks after the end of treatment (SVR12) was 97.4% and 96.7%, respectively, and rapid virological response (RVR) was 75.0% and 57.1%, respectively. SVR12 of GT3a, GT3b, and GT6a was 100%, 83.3%, and 97%, respectively. ALT normality rate in chronic hepatitis group is higher than that in cir...Continue Reading
References
Jun 18, 2010·Journal of Hepatology·Wai-Kay SetoMan-Fung Yuen
Nov 23, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Khayriyyah Mohd HanafiahSteven T Wiersma
Oct 5, 2013·Journal of Gastroenterology and Hepatology·Huiying RaoHui Zhuang
Jul 30, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jane P MessinaEleanor Barnes
Dec 10, 2016·Journal of Viral Hepatitis·S AlonsoC M Fernández-Rodríguez
Jan 7, 2017·Liver International : Official Journal of the International Association for the Study of the Liver·Giuseppe CabibboUNKNOWN ITA.LI.CA study group
Feb 19, 2017·The Lancet Oncology·Alessandro Granito, Luigi Bolondi
Apr 12, 2017·The Lancet. Gastroenterology & Hepatology·UNKNOWN European Union HCV Collaborators
Apr 26, 2017·The American Journal of Gastroenterology·Mei-Hsuan LeeMindie H Nguyen
Nov 2, 2017·Emerging Microbes & Infections·Ying ChenJinlin Hou
Nov 18, 2017·BMC Infectious Diseases·Hosnieh FathiGeoffrey Dusheiko
Jan 25, 2018·The New England Journal of Medicine·Stefan ZeuzemFederico J Mensa
Mar 15, 2018·Alimentary Pharmacology & Therapeutics·J von FeldenS Christensen
Apr 14, 2018·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Nov 1, 2018·Journal of Viral Hepatitis·Dong-Bo WuHong Tang
Apr 5, 2019·PloS One·Peter BuggischJoerg Petersen
Apr 9, 2019·Journal of Hepatology·Giuseppe CabibboUNKNOWN Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group
Apr 17, 2019·Cells·Alessandra MangiaAlessia Ciancio
Jul 4, 2019·Clinics in Liver Disease·Rashed AbdelaalMohamed El Kabany
Aug 20, 2019·Scandinavian Journal of Gastroenterology·Midori KjellinJohan Lennerstrand
Aug 23, 2019·Journal of Hepatology·Elisabetta DegasperiUNKNOWN NAVIGATORE-Lombardia and Veneto Study Groups
Aug 27, 2019·Endocrine, Metabolic & Immune Disorders Drug Targets·Hanan SolimanSherief Abd-Elsalam
Aug 30, 2019·Hepatology International·Chung-Feng HuangUNKNOWN REAL-C Investigators
Oct 5, 2019·Expert Review of Anti-infective Therapy·Fiona McPhee
Nov 28, 2019·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Chen-Ta ChiYi-Hsiang Huang
Dec 4, 2019·Journal of Hepatology·Chen-Hua LiuJia-Horng Kao
Dec 10, 2019·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G GhanyUNKNOWN AASLD-IDSA Hepatitis C Guidance Panel
Dec 11, 2019·Journal of Hepatocellular Carcinoma·Mohamed El KassasAhmed Kaseb